TransMedics is due for a re-rating as it becomes a fully integrated logistics network for organ transplants, not just a device maker. Its 22 aircraft flew nearly 9,000 missions last year, supporting about 26% of US transplants. It targets 10,000 US cases by 2028 and 30,000 globally by 2032, helped by a kidney platform, and projects revenue rising from $605 million to $2.5-3 billion in four to five years. It is high risk, high reward, with a possible 100%+ rebound in two to three months. x.com  … Show more

TransMedics' long-term story stands despite a roughly 60% stock drop, because its organ transplant model is hard to replicate. It sells the machines and also handles retrieval and transport with its own aviation fleet and clinical teams. Margins are compressed by deliberate heavy investment, alongside regulatory issues and a lingering short report. About three-quarters of the TAM remains in the US, Europe is opening through Italy and PAD Aviation, and kidney transplants could double the TAM. … Show more

TransMedics' capital allocation adds risk, turning the stock into a show-me story despite results that mathlonning's recap calls solid. Its non-core charter business in Europe brings incrementally more execution risk and margin dilution, and it is questionable whether the company keeps pricing power as oil drops. Spending $12m on consultants is not a great look either. x.com 

TransMedics is undervalued and could reach about $400 a share by 2032 as Europe and kidneys add new revenue. Its CEO says Europe is about half the global transplant opportunity, yet generates only about $20M today, and he forecasts 30,000 transplants and $2B of revenue by 2032, an 18% annual growth rate. Revenue from kidneys and Europe starts in the second half of 2027. At 40% EBITDA margins that is $800M of EBITDA, and 20x gives about $400. A director and the CEO have bought shares. x.com 

TransMedics' long-term case is not threatened by high oil prices or Chinese regeneration drugs. It partly passed logistics costs on to hospitals last quarter, and the regeneration therapies @chillthehate cites look like a risk perhaps a decade out. @Stavanger68's FY29 assumptions of about $1.67B revenue and $9.5 EPS are aggressive but broadly aligned. Kidney could drive FY28-29 growth, though med-device launches usually take years to gain traction. x.com  x.com  x.com  x.com 

TransMedics' investment case is broken because operating margins are tracking near 11% instead of the expected path above 21%, and management is signaling further near-term pressure as investment continues. That gap is too large to stay invested. x.com 

TransMedics has a moat nobody else can replicate in its dedicated aviation network for organ logistics, as its technology changes heart, lung and liver transplants by keeping donor organs alive and warm in transport. Q1 2026 revenue rose 21% to $174 million, and full-year guidance is $727 million to $757 million. x.com 

TransMedics still looks undervalued even at $94 after a strong Q2 earnings report, which puts it back on the buy list. The company has quietly been crushing it. x.com 

TransMedics' best trade is likely over: in biotech, by the time competition starts being discussed, most of the gain has been made. Another investor notes its technology is great but very expensive, with many working to replace it. x.com 

Better underwriting at Root, AI data demand at Innodata, defense breadth at Applied Aerospace & Defense, scaled voice AI at SoundHound, more organ access via TransMedics, profitable insurance at Lemonade, autonomous defense at Ondas and successful medicines at AbCellera could drive outsized growth. These eight smaller companies have a realistic path to 5x+ over 5-10 years if they execute on those opportunities. x.com  x.com  x.com  x.com  x.com  x.com  x.com  x.com